VaxEquity

VaxEquity is a biotechnology company founded in 2020 by Professor Robin Shattock, head of infection immunology at Imperial College London, and led by a world-class team of pioneers in the RNA field. By utilizing its next-generation self-amplifying RNA (saRNA) platform, it expands the impact of RNA vaccines and therapies. The company uses saRNA to deliver significantly enhanced protein expression, combining better tolerance with slower release and thermal stability. VaxEquity is a pioneer in next-generation approaches, overcoming current limitations by modulating immune responses through modifications to its saRNA. The flexibility of the company’s platform ensures a broad pipeline of assets that can be designed, developed, and manufactured rapidly and at scale.